August 14, 2024 - CTV is a better way to find clinical trials. Find trials for common conditions, or customize your search with location, treatment, and status filters.

Access 160+ million publication pages and connect with 25+ million researchers. Join for free and gain visibility by uploading your research.

November 14, 2024 - Emavusertib (CA-4948) is a drug which acts as a selective inhibitor of the enzyme Interleukin-1 receptor-associated kinase 4 (IRAK-4) and was developed for the treatment of some forms of cancer.

Emavusertib (CA-4948) hydrochloride is a selective, potent and orally active IRAK4/FLT3 inhibitor. Emavusertib hydrochloride has an IC50 of 57 nM for IRAK4 in a FRET kinase assay. Emavusertib hydrochloride shows anti-tumor activity. - Mechanism of Action & Protocol.

May 15, 2024 - /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...

A multicenter, phase I/II, open-label clinical trial (with an estimated/planned enrollment of 221 patients) is evaluating the administration of emavusertib (CA-4948) in patients with relapsed/refractory B-cell NHL (NCT03328078). Part A of this clinical trial will evaluate escalating doses of ...

February 13, 2024 - The IRAK-4 and FLT-3 inhibitor emavusertib (previously CA-4948) demonstrated a favorable safety profile and early signs of antitumor activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia (AML) harboring FLT3 mutations, some of whom also expressed the spliceosome ...

Additional Study Information: The purpose of this study is to test the safety of a drug called CA-4948 in combination with gemcitabine and nab-paclitaxel. This study tests different doses of the drug CA-4948 to see which dose is safer for people. There will be about 36 people taking part in ...

February 28, 2024 - CA-4948 (emavusertib) is a kinase inhibitor that blocks the action of certain mutated proteins that signal cancer cells to multiply. The drug has been tested in cancers like non-Hodgkin’s lymphoma, acute myeloid leukemia, and myelodysplastic syndromes.

This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). Patients enrolling in the Phase 1 portion of the study ...

National Cancer Institute at the National Institutes of Health

April 6, 2023 - A new study published in Clinical Cancer Research revealed that inhibition of the IRAK-4 protein with a small molecule inhibitor called CA-4948 can downregulate the expression of transcription factors related to cancer, even inside the blood-brain barrier. This discovery could have significant ...

MYD88-L265P encoding mutations occur in diffuse large B-cell lymphomas, in lymphoplasmacytic lymphomas and in few marginal zone lymphomas (MZL). The IRAK4 inhibitor emavusertib (CA-4948) has shown early safety and clinical activity in lymphoma and leukemia patients.

One of the largest and most authoritative collections of online journals, books, and research resources, covering life, health, social, and physical sciences.